New crystalline forms of norpsilocin create new options for developing psychedelic drug formulations.
Understanding brain morphology differences may prove essential for creating effective psychedelic drug formulations.
Environment and diet may play a role in the alkaloid content of secretions from a Brazilian toad species.
Researchers took the psilocybin-making genes from P. cubensis and put them into S. cerevisiae allowing them to produce psilocybin, several of its analogs, and a “new to nature” compound.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Pain was inhibited by an α2-adrenoceptor antagonist and reduced by an α1-adrenoceptor antagonist. Opioid receptors may also be involved in the effects.
Results hint at a possible mechanism for the persistent effect that psilocybin has on mindfulness.
Greater potency means doing more with less. But does norpsilocin even have a role in the psychedelic effect?
This is the second crystal structure of this compound, providing additional options for developing psychedelics into therapeutic drug formulations.
Baeocystin does not cause the head twitch in mice, but its metabolite norpsilocin is more potent than psilocin.